Therapy for hyperglycemia, related disorders and erectile dysfunction

Abstract

The invention relates to a methods, compositions and kits for treating hyperglycemia and related disorders, such as type 2 diabetes mellitus, impaired glucose tolerance, diabetic retinopathy, diabetic nephropathy and diabetic neuropathy, and to methods, compositions and kits for treating erectile dysfunction. The methods comprise administering an inhibitor of fatty acid oxidation to a subject in need thereof. In some embodiments, trimetazidine and metformin or a phosphodiesterase 5 inhibitor are administered.

Description

[0001] related application [0002] This application claims the benefit of priority to US Provisional Application No. 60 / 905,934, filed March 9, 2007, the entire teachings of which are incorporated herein by reference. Background of the invention [0003] Type 2 diabetes (T2DM), the most common form of diabetes, occurs when the body does not produce sufficient amounts of insulin, a hormone that causes cells to take up glucose from the blood, or when cells resist the biological effects of insulin. As a result, cells are deprived of their basic energy source, glucose, and glucose levels in the blood accumulate to pathological levels. T2DM has reached pandemic levels, affecting more than 150 million people worldwide. The prevalence of the disease is expected to increase to 300 million people by 2025. Although weight control has the potential to reduce this pandemic, increased availability of low-cost / high-calorie foods and sedentary lifestyles have fueled obesity and subsequent...

AI Technical Summary

Problems solved by technology

However, these types of therapies are not suitable for all patients, as phosphodiesterase 5 inhibitors are contraindicated in patients on organic nitrates and are ineffective if the patient has impaired NO production in the corpus cavernosum

Images